Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Taylor H. Schreiber
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Beta
- 1.11
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 37.30
Financials
Revenue
$0.00-100.0%Net Income
$-15.15MEBITDA
$-13.75MFree Cash Flow
$-10.33MEPS (diluted)
$-0.12Shares Outstanding (diluted)
129.78M+1623.7%Operating Expenses
$16.16MCash & Debt
$63.30MReturn of Capital
$0.00Revenue by Segment (annual)
$3.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.00M | $-48.81M | $-0.70 |
| 2024 | $5.72M | $-75.41M | $-1.49 |
| 2023 | $1.66M | $-87.30M | $-2.05 |
| 2022 | $652.0K | $-101.94M | $-2.41 |
| 2021 | $30.02M | $-44.97M | $-1.07 |
| 2020 | $9.93M | $-36.60M | $-0.88 |
| 2019 | $9.89M | $-23.98M | $-0.57 |
| 2018 | $22.44M | $-7.39M | $-0.49 |
Valuation
STTKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+100.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·6h ago·Positive
…ncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and durable receptor occupancy, supporting quarterly dosing potential. STTK is fully funded through Phase 2b efficacy readout, with cash runway into 2029 despite significant dilution; valuation trades at a forward price-to-book discount.
View source ↗ - Newsfool.com·7d ago·Negative
What Shattuck Labs Stock Topped the Market on Monday One of them initiated coverage. The company has a very promising lead drug candidate.
View source ↗
Earnings
Tue, Nov 10(in 2 months)
Consensus estimate $-0.10 per share
Typical surprise +4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.12 vs $-0.12beat
- Thu, May 7$-0.13 vs $-0.14beat
- Thu, Mar 5$-0.12 vs $-0.12beat
- Thu, Nov 6$-0.14 vs $-0.15beat
- Thu, Aug 14$-0.24 vs $-0.25beat
- Thu, May 1$-0.27 vs $-0.29beat
Estimates and results for STTK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STTK officers and directors.
- Bought
- $51.2m
- Sold
- $592k
17 trades
6 trades
- Shukla Abhinav A.sold
- Shukla Abhinav A.sold
- Shukla Abhinav A.sold
- Pandite Arundathy N.sold
- Ashiya Monabought
- Ashiya Monabought
- Orbimed Advisors Llcbought
- Orbimed Advisors Llcbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.